- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05461339
TAB014 Compared to Lucentis® in Patients With Neovascular Age-related Macular Degeneration (nAMD)
March 2, 2023 updated by: TOT Biopharm Co., Ltd.
A Phase III, Randomized, Multicenter, Doubled-blind Clinical Trial Comparing the Efficacy and Safety of TAB014 and Lucentis in Neovascular Age-related Macular Degeneration (nAMD) Patients
This study is a randomized, multi-center, double blind, Lucentis controlled non-inferiority study in neovascular age-related macular degeneration patients.
The objective of this study is to compare the efficacy and safety of TAB014 and ranibizumab (Lucentis).
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
Primary Objectives:
To evaluate the efficacy of TAB014 compared to Lucentis in neovascular age-related macular degeneration patients
Secondary Objectives:
- To evaluate the safety of TAB014 compared to Lucentis in neovascular age-related macular degeneration patients.
- To evaluate the immunogenicity of TAB014 in neovascular age-related macular degeneration patients.
Study Type
Interventional
Enrollment (Anticipated)
488
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Junping Hong, PhD
- Phone Number: 86-010-85979677
- Email: hongjunping@totbiopharm.com
Study Contact Backup
- Name: Xiaolei Zhang
- Phone Number: 86-15041487081
- Email: zhangxiaolei@totbiopharm.com
Study Locations
-
-
-
Beijing, China, 100730
- Recruiting
- Peking Union Medical College Hospital
-
Contact:
- Youxin Chen, PhD
- Email: chenyouxinpumch@163.com
-
Principal Investigator:
- YouXin Chen, PhD
-
-
Anhui
-
Hefei, Anhui, China, 230601
- Recruiting
- The Second Hospital of Anhui Medical University
-
Contact:
- Qian Zhang
- Phone Number: 86-0551-63806050
- Email: officegcp@ayefy.com
-
-
Beijing
-
Beijing, Beijing, China, 100191
- Recruiting
- Peking University Third Hospital
-
Contact:
- Xiaoye Niu
- Phone Number: 86-010-82265757
- Email: bysygcp@163.com
-
Beijing, Beijing, China, 100044
- Recruiting
- Peking University People's Hospital
-
Contact:
- Danjie Guo
- Phone Number: 86-010-88324074
- Email: guodanjie@pkuph.edu.ch
-
Beijing, Beijing, China, 100730
- Recruiting
- Beijing Hospital
-
Contact:
- Yan Li
- Phone Number: 86-010-58115073
- Email: bjyygcp@126.com
-
Beijing, Beijing, China, 100021
- Recruiting
- Beijing Aier Intech Eye Hospital
-
Contact:
- Xiaoai Long
- Phone Number: 86-010-67732909
- Email: eye010bjllwyh@163.com
-
Beijing, Beijing, China, 100730
- Recruiting
- Beijing Tongren Hospital, Cmu
-
Contact:
- Yuyang Dai
- Phone Number: 86-010-58268486
- Email: bjtrgcp@163.com
-
-
Changchun
-
Jilin, Changchun, China, 130021
- Recruiting
- The First Hospital of Jilin University
-
Contact:
- Fei Wang
- Phone Number: 86-0431-88786014
- Email: wangfei5780@126.com
-
-
Chongqing
-
Chongqing, Chongqing, China, 400016
- Not yet recruiting
- The First Affiliated Hospital of Chongqing Medical University
-
Contact:
- Hui Yang
- Phone Number: 86-023-89012224
- Email: CQ_GCP@163.com
-
-
Fujian
-
Amoy, Fujian, China, 361004
- Not yet recruiting
- Xiamen Eye Center of Xiamen University
-
Contact:
- Wenjie Huang
- Phone Number: 86-0592-2367670
- Email: xmykcto@huaxiaeye.com
-
Fuzhou, Fujian, China, 350005
- Recruiting
- The First Affiliated Hospital of Fujian Medical University
-
Contact:
- Anpeng Wu
- Phone Number: 86-0591-87981029
- Email: fjydfyjg@163.com
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510180
- Recruiting
- Guangzhou First People's Hospital
-
Contact:
- Huiqin Ni
- Phone Number: 86-020-81048106
- Email: syjg0319@126.com
-
Guangzhou, Guangdong, China, 510080
- Recruiting
- The First Affiliated Hospital, Sun Yat-sen University
-
Contact:
- Lei Tang
- Phone Number: 86-020-87331952
- Email: ctc1983@mail.sysu.edu.cn
-
Guangzhou, Guangdong, China, 510260
- Recruiting
- The Second Affiliated Hospital of Guangzhou Medical
-
Contact:
- Ke Han
- Phone Number: 86-020-34153066
- Email: gyeyyx@163.com
-
Guangzhou, Guangdong, China, 510623
- Not yet recruiting
- Zhongshan Ophthalmic Center, Sun Yat-sen University
-
Contact:
- Xiang Chen
- Phone Number: 86-020-66610720
- Email: zoccrc@mail.sysu.edu.cn
-
Shantou, Guangdong, China, 515041
- Not yet recruiting
- Joint Shantou International Eye Center of Shantou University and The Chinese University of Hong Kong
-
Contact:
- Junfeng Zhu
- Phone Number: 86-0754-88393578
- Email: gcp@jsiec.org
-
Shenzhen, Guangdong, China, 518031
- Recruiting
- Shenzhen Aier Eye Hospital
-
Contact:
- Hongxia Liao
- Phone Number: 86-0755-83321028
- Email: 278452768@qq.com
-
-
Guizhou
-
Guiyang, Guizhou, China, 550004
- Recruiting
- The Affiliated Hospital of Guizhou Medical University
-
Contact:
- Yan He
- Phone Number: 86-0851-86776395
- Email: zhouyan800320@163.com
-
Zunyi, Guizhou, China, 563000
- Recruiting
- Affiliated Hospital of Zunyi Medical University
-
Contact:
- Chen Wang
- Phone Number: 86-0851-28608210
- Email: zyfyjg2011@163.com
-
-
Hebei
-
Cangzhou, Hebei, China, 061017
- Recruiting
- Cangzhou Central Hospital
-
Contact:
- Yanrong Wang
- Phone Number: 86-0317-2072825
- Email: czzxyygcp@126.com
-
Xingtai, Hebei, China, 054001
- Recruiting
- Hebei Eye Hospital
-
Contact:
- Shanxue Li
- Phone Number: 86-0319-3237686
- Email: hbsykyygcp@126.com
-
-
Heilongjiang
-
Ha'erbin, Heilongjiang, China, 150001
- Recruiting
- The First Affiliated Hospital Of Harbin Medical University
-
Contact:
- Xiaohui Ren
- Phone Number: 0451-85552933
- Email: Renxiaohui2004@163.com
-
-
Henan
-
Kaifeng, Henan, China, 475000
- Recruiting
- Kaifeng Central Hopital
-
Contact:
- Yongshuang Hao
- Phone Number: 86-15226075751
- Email: kjb5672645@126.com
-
Zhengzhou, Henan, China, 450052
- Recruiting
- The First Affiliated Hospital of Zhengzhou University
-
Contact:
- Wenhua Xue
- Phone Number: 86-0371-66295624
- Email: ZDYFYgcp@163.com
-
Zhengzhou, Henan, China, 450008
- Recruiting
- Henan Eye Hospital& Henan Eye Institute
-
Contact:
- Huijuan He
- Phone Number: 86-0371-67120925
- Email: hnykzx@126.com
-
Zhengzhou, Henan, China, 450015
- Recruiting
- Zhengzhou Second Hospital
-
Contact:
- Huizhi Zhang
- Phone Number: 86-0371-68993626
- Email: zzseylx@126.com
-
-
Hubei
-
Shiyan, Hubei, China, 442000
- Recruiting
- Taihe Hospital (Affiliated Hospital of Hubei University of Medicine)
-
Contact:
- Che Zhang
- Phone Number: 86-0719-8801691
- Email: prof.zh@163.com
-
Wuhan, Hubei, China, 430060
- Recruiting
- Renmin Hospital of Wuhan University
-
Contact:
- Jian Zhou
- Phone Number: 86-027-88237069
- Email: 3375565387@qq.com
-
Wuhan, Hubei, China, 430081
- Recruiting
- Wuhan Puren Hospital
-
Contact:
- Dunyao Bai
- Phone Number: 86-027-86360089
- Email: prjgb_gcp@126.com
-
Wuhan, Hubei, China, 430030
- Recruiting
- Tongji Hospital® Tongji Medical Collehe of Hust
-
Contact:
- Chang Shu
- Phone Number: 86-027-83663625
- Email: tongjigcp@163.com
-
Wuhan, Hubei, China, 430070
- Recruiting
- Central theater General Hospital
-
Contact:
- Xioachun Wu
- Phone Number: 86-027-50772999
- Email: 13554419142@163.com
-
-
Hunan
-
Changsha, Hunan, China, 410008
- Recruiting
- Xiangya Hospital of Central South University
-
Contact:
- Qun Qin
- Phone Number: 0731-84327918
- Email: xyyygcp2010@126.com
-
Changsha, Hunan, China, 410015
- Recruiting
- Aier Eye Hospital(Changsha)
-
Contact:
- Li Lin
- Phone Number: 86-731-85229669
- Email: gcpcseyejg@163.com
-
-
Inner Mongolia
-
Hohhot, Inner Mongolia, China, 010030
- Not yet recruiting
- The Affiliated Hospital of Inner Mongolia Medical University
-
Contact:
- Zhi Guo
- Phone Number: 86-0471-3451606
- Email: mmm1965@163.com
-
-
Jiangsu
-
Wuxi, Jiangsu, China, 214002
- Recruiting
- Wuxi No.2 People's Hospital
-
Contact:
- Liping Wang
- Phone Number: 86-0510-68563496
- Email: wx2hgcp@126.com
-
-
Jiangxi
-
Nanchang, Jiangxi, China, 330008
- Recruiting
- The Second Affiliated Hospital of Nanchang University
-
Contact:
- Jian Li
- Phone Number: 86-0791-86297032
- Email: efyjgb@126.com
-
Nanchang, Jiangxi, China, 330006
- Recruiting
- Affiliated Eye Hospital of Nanchang University
-
Contact:
- Lin Yuan
- Phone Number: 86-13803527527
- Email: 361188958@qq.com
-
-
Liaoning
-
Dalian, Liaoning, China, 116091
- Recruiting
- Dalian No.3 People'S Hospital
-
Contact:
- Junshu Jiang
- Phone Number: 86-18141159890
- Email: dlsyjgb@163.com
-
Shenyang, Liaoning, China, 110000
- Recruiting
- The Fourth People's Hospital of Shenyang
-
Contact:
- Peijun Li
- Phone Number: 86-024-86203666
- Email: 2865762948@qq.com
-
Shenyang, Liaoning, China, 110034
- Recruiting
- Shenyang He Eye Hospital
-
Contact:
- Huidong Ren
- Phone Number: 86-024-26716768
- Email: gcp@hsyk.com.cn
-
-
Shandong
-
Jinan, Shandong, China, 250021
- Not yet recruiting
- Jinan 2Nd People'S Hospital
-
Contact:
- Yang Feng
- Phone Number: 86-15066672082
- Email: eyywlcsyjg@163.com
-
Weifang, Shandong, China, 261041
- Recruiting
- Weifang Eye Hospital Co., Ltd.
-
Contact:
- Pengfei Jiang
- Phone Number: 86-18363691272
- Email: wfykyyjgb@163.com
-
-
Shanghai
-
Shanghai, Shanghai, China, 200080
- Not yet recruiting
- Shanghai General Hospital
-
Contact:
- Xueying Ding
- Phone Number: 021-36126424
- Email: shiyigcp@126.com
-
Shanghai, Shanghai, China, 200041
- Not yet recruiting
- Shanghai Eye Disease Prevention and Treatment Center
-
Contact:
- Tianxiao Wang
- Phone Number: 86-021-52666721
- Email: wtxcrco@shsyf.com
-
Shanghai, Shanghai, China, 200072
- Recruiting
- Shanghai Tenth People's Hospital(Tenth People's Hospital of Tongji Unversity)
-
Contact:
- Fei Teng
- Phone Number: 86-021-66301539
- Email: sy_gcp@126.com
-
-
Shanxi
-
Changzhi, Shanxi, China, 046000
- Recruiting
- Changzhi People's Hospital
-
Contact:
- Na Si
- Phone Number: 86-15235503549
- Email: xfywlc2024990@126.com
-
Jinzhong, Shanxi, China, 030699
- Recruiting
- The First People's Hospital of Jinzhong(Jinzhong Hospital Affiliated to Shanxi Medical University)
-
Contact:
- Shu Wang
- Phone Number: 86-15135410703
- Email: jzyyjgb@163.com
-
Taiyuan, Shanxi, China, 030002
- Recruiting
- Shanxi Eye Hospital
-
Contact:
- Ruizhong Gong
- Phone Number: 86-13513632987
- Email: sxykywjg@163.com
-
Xi'an, Shanxi, China, 710002
- Recruiting
- Xi'an No.1 Hospital
-
Contact:
- Yajuan Wang
- Phone Number: 86-13992882631
- Email: 674653449@qq.com
-
Xi'an, Shanxi, China, 710004
- Recruiting
- Xi'an Fourth Hospital
-
Contact:
- Xiaoyu Yang
- Phone Number: 86-029-89621336
- Email: 23749115@qq.com
-
-
Sichuan
-
Chengdu, Sichuan, China, 610041
- Recruiting
- Chengdu Aier Eye Hospital
-
Contact:
- Min He
- Phone Number: 86-028-87010707
- Email: 1437663403@qq.com
-
Chengdu, Sichuan, China, 610084
- Recruiting
- Ineye Hospital of Chengdu University of TCM
-
Contact:
- Xiaoying Yang
- Phone Number: 86-15811096821
- Email: Ineye_gcp@163.com
-
-
Tianjin
-
Tianjin, Tianjin, China, 300020
- Recruiting
- TianJin eye hospital
-
Contact:
- Yi Zhang
- Phone Number: 86-15522516709
- Email: tjsykyy@163.com
-
Tianjin, Tianjin, China, 300384
- Not yet recruiting
- Tianjin Medical University Eye Hospital
-
Contact:
- Huiyu Wei
- Phone Number: 86-022-86428883
- Email: tjykgcp@126.com
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310014
- Recruiting
- Zhejiang Provincial People's Hospital
-
Contact:
- Ying Wang
- Phone Number: 86-0571-85893646
- Email: zjsrmyygcp@163.com
-
Hangzhou, Zhejiang, China, 310003
- Recruiting
- The First Affiliated Hospital, Zhejiang University School of Medicine (FAHZU)
-
Contact:
- You Di
- Phone Number: 86-0571-87236560
- Email: zyct79@163.com
-
Wenzhou, Zhejiang, China, 325027
- Recruiting
- Eye Hospital, WMU
-
Contact:
- Zhishu Bao
- Phone Number: 86-0577-88068860
- Email: wz88068860@163.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
50 years to 90 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients must be > 50 years old, male or female;
- Confirmed active subfoveal or juxtafoveal choroidal neovascularization (CNV) secondary to nAMD in the study eye;
- BCVA letter score between 15 and 73 (inclusive) by the ETDRS chart during the screening period ;
Confirmed by independent central reading center:
- Total lesion area ≤ 12 optic disc areas in the study eye,
- Fibrotic, scarring or atrophy < 50% of total lesion area, without involving the fovea,
- Retinal hemorrhage involving the foveal or intraretinal hemorrhage < 4 optic disc area,
- Able to understand and personally sign informed consent form.
Exclusion Criteria:
Ophthalmic Treatment history:
- Intravitreal injection of an anti-VEGF drug (ranibizumab, bevacizumab, aflibercept or conbercept, etc.) in any eye within 90 days prior to randomization;
- Prior vitrectomy, panretinal photocoagulation, laser treatment of the foveal area or ocular treatment/surgery for nAMD in the study eye; or history of corneal transplantation or corneal dystrophy, treatment with verteporfin, external radiation therapy of the head or the eye, transpupillary hyperthermia;
- Prior intra-ocular (including cataract) surgery in the study eye within 90 days before randomization, or surgery to the exterior eye within 28 days before randomization;
- Intravitreal therapy in the study eye (e.g. steroids or device implants) within 180 days before randomization;
- PDT (Photodynamic Therapy) in the non-study eye within 30 days before screening;
- Central serous chorioretinopathy (CSC) in the study eye;
- The non-study eye confirmed to have a BCVA on ETDRS chart of < 18 letters during screening;
- Myopia more than -8.0 diopters of refractive error in study eye; For patients who have undergone refractive surgery or cataract surgery, refraction must not have been greater than -8.0 diopters prior to surgery;
- Absence of the crystalline lens (unless there has been artificial lens replacement), or presence of posterior lens capsule rupture, or YAG laser posterior capsulotomy received 30 days before randomization or expect to receive during the study period in study eye;
- Ocular disorders in the study eye as determined by the investigator at the present time: (a) effects on the central vision, or (b) increasing safety risk for the subject, or (c) affecting efficacy, safety evaluation or sampling, or (d) having ocular diseases requiring surgical or medical intervention
- In the study eye, (a) presence of uncontrolled glaucoma at randomization, or (b) prior glaucoma surgery, or (c) advanced glaucoma or optic neuropathy, affecting or endangering the central visual field;
- Active intraocular, extraocular, or periocular inflammation or infection in either eye at randomization;
- History of idiopathic or autoimmune-associated uveitis in either;
- Active Hepatitis B, C or syphillis; HIV antibody positive; presence of any immune deficient, and/or immune suppressed illnesses;
- Poorly controlled hypertension after receiving the best possible therapy;
- Diabetic patients with HbA1c >10%;
- Any unmanageable clinical illness; Severe liver and kidney abnormalities;dysfunction of blood coagulation; cardiovascular events within 180 days before randomization and determined by investigator can affect subject safety evaluation or increase subject risk;
- Prior significant allergic reactions to biological products, or known allergic reactions to bevacizumab, ranibizumab, or study related medication (including fluorescein or indocyanin green), pupillary dilating agents, anaesthetic agents, or anti-infective agents;
- Anti-VEGF therapy within 90 days prior to randomization; subjects are allowed to take any dietary supplements, vitamins or minerals;
- Continuous systemic use ≥ 30days of corticosteroids within 90 days before randomization, or systemic use of corticosteroids within 5 days before randomization;
- Necessity to continue use of prohibited agents (drugs known to be toxic to the lens, retina, or optic nerve, including deoxyamine, chloroquine/hydroxychloroquine (braquinib), tamoxifen, phenothiazines, and ethambutol);
- Participation in a study trial involving any drug or device therapy (other than vitamins and minerals) within 90 days prior to randomization; And the use of any other experimental drugs or experimental interventions other than those of this study (e.g. isostoluent blood thinning, intravitreal tissue plasminogen activators) is prohibited during the study period;
- Pregnant or lactating women, or those with plans for pregnancy during or within 6 months of study termination (including male subjects). Premenopausal woman testing positive for pregnancy during screening or is reluctant to use reliable contraceptive methods during the study periods;
- Other conditions that are considered not acceptable to be enrolled in the study by the investigator.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: TAB014
intravitreal injection at 1.25mg once every 4 week
|
intravitreal injection at 1.25mg once every 4 weeks
Other Names:
|
Active Comparator: Ranibizumb
intravitreal injection at 0.5mg once every 4 week
|
intravitreal injection at 0.5mg once every 4 weeks
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluate the change in BCVA of the study eye from TAB014 and ranibizumab treatment groups.
Time Frame: At week 52
|
Best-corrected visual acuity (BCVA) letter score as measured by the ETDRS chart
|
At week 52
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluate the change in BCVA of the study eye
Time Frame: At week 12, 24 and 36
|
Best-corrected visual acuity (BCVA) letter score as measured by the ETDRS chart
|
At week 12, 24 and 36
|
Evaluate the proportion of subjects with an increase in BCVA of >5, >10, and >15 in the study eye
Time Frame: At week 12, 24 and 52
|
Best-corrected visual acuity (BCVA) letter score as measured by the ETDRS chart
|
At week 12, 24 and 52
|
Evaluate the proportion of subjects with a BCVA loss of <5, <10, < 15 letters in the study eye
Time Frame: At week 12, 24 and 52
|
Best-corrected visual acuity (BCVA) letter score as measured by the ETDRS chart
|
At week 12, 24 and 52
|
Change in central subfield thickness(CST) in the study eye
Time Frame: At week 12, 24, 36 and 52
|
CST measured by SD-OCT as assessed by independent central reading center
|
At week 12, 24, 36 and 52
|
Change in Choroidal Neovascularization (CNV) area of study eye
Time Frame: At week 12, 24 and 52
|
CNV as assessed by independent central reading center
|
At week 12, 24 and 52
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety Evaluation
Time Frame: Baseline and every month up to week 52
|
Ocular and non-ocular adverse events, serious adverse events (SAEs), adverse events of special interest (AESI), etc. will be graded according to the Ophthalmic Adverse Event Grading Scale and NIA Guidelines for Adverse Events and Serious Adverse Events (September 2018 Edition).
|
Baseline and every month up to week 52
|
Immunogenicity Evaluation
Time Frame: At week 12, 24 and 52
|
Detection of anti-drug antibody and/or neutralizing antibodies will be examined in approximately 80 patients with monocular nAMD and no prior anti-VEGF therapy in the non-study eye for detection of immunogenicity evaluation.
|
At week 12, 24 and 52
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: YouXin Chen, PHD, Peking Union Medical College Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 28, 2022
Primary Completion (Anticipated)
March 1, 2024
Study Completion (Anticipated)
March 1, 2024
Study Registration Dates
First Submitted
July 12, 2022
First Submitted That Met QC Criteria
July 14, 2022
First Posted (Actual)
July 18, 2022
Study Record Updates
Last Update Posted (Estimate)
March 3, 2023
Last Update Submitted That Met QC Criteria
March 2, 2023
Last Verified
March 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Eye Diseases
- Retinal Degeneration
- Retinal Diseases
- Macular Degeneration
- Wet Macular Degeneration
- Physiological Effects of Drugs
- Antineoplastic Agents
- Immunologic Factors
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Ranibizumab
- Antibodies
- Antibodies, Monoclonal
Other Study ID Numbers
- TOT-CR-TAB014-III-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neovascular Age-related Macular Degeneration
-
Novartis PharmaceuticalsCompletedNeovascular Age-Related Macular DegenerationChina
-
Hoffmann-La RocheWithdrawnNeovascular Age-Related Macular DegenerationDenmark, Argentina, Hong Kong, Thailand, Portugal, Greece, Spain
-
Novartis PharmaceuticalsCompletedNeovascular Age-Related Macular DegenerationSpain, Italy, Germany, Canada, Ireland
-
Novartis PharmaceuticalsTerminatedNeovascular Age-Related Macular Degeneration
-
Regeneron PharmaceuticalsCompletedNeovascular Age Related Macular DegenerationUnited States
-
Hoffmann-La RocheRecruitingNeovascular Age Related Macular Degeneration | nAMDChina
-
Innostellar Biotherapeutics Co.,LtdRecruitingNeovascular Age-Related Macular DegenerationChina
-
Hoffmann-La RocheRecruitingNeovascular Age-Related Macular DegenerationBelgium, United States, United Kingdom, Italy, Argentina, Spain, Israel, Australia, Austria, Brazil, Germany, Switzerland, Taiwan, France
-
Hoffmann-La RocheCompletedNeovascular Age-Related Macular DegenerationUnited States
-
Novartis PharmaceuticalsCompletedNeovascular Age Related Macular DegenerationUnited States
Clinical Trials on TAB014 Monoclonal Antibody Injection
-
Lee's Pharmaceutical LimitedUnknown
-
Beijing VDJBio Co., LTD.Completed
-
Cancer Institute and Hospital, Chinese Academy...Unknown
-
CARsgen Therapeutics Co., Ltd.Shanghai East HospitalActive, not recruitingGastric Cancer | Pancreatic Adenocarcinoma | Solid TumorChina
-
Beijing VDJBio Co., LTD.RecruitingIdiopathic Multicentric Castleman's DiseaseChina
-
Shanghai Henlius BiotechRecruitingCutaneous Squamous Cell CarcinomaChina
-
Shanghai Henlius BiotechNot yet recruiting
-
Henlix, IncUnknown
-
Shanghai HyaMab Biotech Co.,Ltd.RecruitingLocally Advanced/Metastatic Solid TumorsChina
-
Bio-Thera SolutionsNot yet recruiting